glp 1 receptor agonist moa Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics Glucagon‐like peptide agonists: A prospective

However, the potential for a drug that can address hair loss and reverse some aging effects has a significant commercial interest, so further research on FOXO4-DRI is being pursued

Based on these observations, we hypothesize that AsGGT1 and AsGGT2, which exhibit high-affinity for -glutamyl- S -allyl-L-cysteine, would contribute to the biosynthesis of alliin in leaves during the formation and maturation of bulbs, while AsGGT3 may contribute to alliin biosynthesis in bulbs during dormancy-breaking or, alternatively, the main in vivo function of AsGGT3 may not be the deglutamylation of -glutamyl- S -allyl-L-cysteine

Compound 38 showed the strongest anti-inflammatory activity, reducing inflammation by 49.26%

They dont share metabolic shortcuts

As of mid-2025, no Phase II or Phase III human clinical trial for BPC-157 has been completed and published in a peer-reviewed journal